IBDEI0YN ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17214,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,17214,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,17214,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,17215,0)
 ;;=205.91^^111^1077^64
 ;;^UTILITY(U,$J,358.3,17215,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17215,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,17215,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,17215,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,17216,0)
 ;;=205.92^^111^1077^63
 ;;^UTILITY(U,$J,358.3,17216,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17216,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,17216,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17216,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,17217,0)
 ;;=206.00^^111^1077^6
 ;;^UTILITY(U,$J,358.3,17217,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17217,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,17217,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,17217,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,17218,0)
 ;;=206.01^^111^1077^5
 ;;^UTILITY(U,$J,358.3,17218,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17218,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,17218,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,17218,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,17219,0)
 ;;=206.02^^111^1077^4
 ;;^UTILITY(U,$J,358.3,17219,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17219,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,17219,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17219,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,17220,0)
 ;;=206.10^^111^1077^15
 ;;^UTILITY(U,$J,358.3,17220,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17220,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,17220,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,17220,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,17221,0)
 ;;=206.11^^111^1077^14
 ;;^UTILITY(U,$J,358.3,17221,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17221,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,17221,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,17221,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,17222,0)
 ;;=206.12^^111^1077^13
 ;;^UTILITY(U,$J,358.3,17222,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17222,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,17222,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17222,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,17223,0)
 ;;=206.20^^111^1077^55
 ;;^UTILITY(U,$J,358.3,17223,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17223,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,17223,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,17223,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,17224,0)
 ;;=206.21^^111^1077^54
 ;;^UTILITY(U,$J,358.3,17224,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17224,1,1,0)
 ;;=1^206.21
 ;;^UTILITY(U,$J,358.3,17224,1,8,0)
 ;;=8^Subacute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17224,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,17225,0)
 ;;=206.22^^111^1077^56
 ;;^UTILITY(U,$J,358.3,17225,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17225,1,1,0)
 ;;=1^206.22
 ;;^UTILITY(U,$J,358.3,17225,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,17225,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,17226,0)
 ;;=206.80^^111^1077^41
 ;;^UTILITY(U,$J,358.3,17226,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17226,1,1,0)
 ;;=1^206.80
 ;;^UTILITY(U,$J,358.3,17226,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remission
 ;;^UTILITY(U,$J,358.3,17226,2)
 ;;=^336864
 ;;^UTILITY(U,$J,358.3,17227,0)
 ;;=206.81^^111^1077^40
 ;;^UTILITY(U,$J,358.3,17227,1,0)
 ;;=^358.31IA^8^2
